196 related articles for article (PubMed ID: 35593483)
21. Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Proudman D; Miller A; Nellesen D; Gomes A; Mankoski R; Norregaard C; Sullivan E
JAMA Netw Open; 2020 Nov; 3(11):e2025866. PubMed ID: 33201235
[TBL] [Abstract][Full Text] [Related]
22. Budget Impact Analysis of Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer in Taiwan.
Tsai YL; Chang CJ
Value Health Reg Issues; 2023 May; 35():48-56. PubMed ID: 36863067
[TBL] [Abstract][Full Text] [Related]
23. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
Lee Y; Lee S; Sung JS; Chung HJ; Lim AR; Kim JW; Choi YJ; Park KH; Kim YH
Cancer Res Treat; 2021 Jan; 53(1):123-130. PubMed ID: 32810930
[TBL] [Abstract][Full Text] [Related]
24. ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue.
Mersiades AJ; Solomon BJ; Thomas DM; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OM; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N
Future Oncol; 2024 Mar; 20(7):361-371. PubMed ID: 37767626
[TBL] [Abstract][Full Text] [Related]
25. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system.
Perdrizet K; Stockley TL; Law JH; Smith A; Zhang T; Fernandes R; Shabir M; Sabatini P; Youssef NA; Ishu C; Li JJ; Tsao MS; Pal P; Cabanero M; Schwock J; Ko HM; Boerner S; Ruff H; Shepherd FA; Bradbury PA; Liu G; Sacher AG; Leighl NB
Cancer Treat Res Commun; 2022; 31():100534. PubMed ID: 35278845
[TBL] [Abstract][Full Text] [Related]
26. Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans.
Li Y; Heer AK; Sloane HS; Edelstein DL; Tie J; Gibbs P; Barzi A
JAMA Health Forum; 2024 May; 5(5):e241270. PubMed ID: 38819797
[TBL] [Abstract][Full Text] [Related]
27. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
Ida H; Koyama T; Mizuno T; Sunami K; Kubo T; Sudo K; Tao K; Hirata M; Yonemori K; Kato K; Okusaka T; Ohe Y; Matsui Y; Yamazaki N; Ogawa C; Kawai A; Narita Y; Esaki M; Yamamoto N
Cancer Sci; 2022 Dec; 113(12):4300-4310. PubMed ID: 36106376
[TBL] [Abstract][Full Text] [Related]
29. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer.
Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB
JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057
[TBL] [Abstract][Full Text] [Related]
30. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
31. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
[TBL] [Abstract][Full Text] [Related]
32. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
33. Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model.
Pennell NA; Mutebi A; Zhou ZY; Ricculli ML; Tang W; Wang H; Guerin A; Arnhart T; Dalal A; Sasane M; Wu KY; Culver KW; Otterson GA
JCO Precis Oncol; 2019 Dec; 3():1-9. PubMed ID: 35100695
[TBL] [Abstract][Full Text] [Related]
34. Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring
Stargardter M; McBride A; Tosh J; Sachdev R; Yang M; Ambavane A; Mittal M; Vioix H; Liu FX
J Med Econ; 2021; 24(1):816-827. PubMed ID: 34126842
[TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness of Comprehensive Genomic Profiling in Patients With Non-Small Cell Lung Cancer for the Colombian Health System.
Gamboa O; Bonilla CE; Quitian D; Torres GF; Buitrago G; Cardona AF
Value Health Reg Issues; 2024 Jan; 39():115-125. PubMed ID: 38101152
[TBL] [Abstract][Full Text] [Related]
36. Promising New Agents for Colorectal Cancer.
Das S; Ciombor KK; Haraldsdottir S; Goldberg RM
Curr Treat Options Oncol; 2018 May; 19(6):29. PubMed ID: 29752549
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact.
Johnston KM; Sheffield BS; Yip S; Lakzadeh P; Qian C; Nam J
Curr Oncol; 2020 Dec; 27(6):e569-e577. PubMed ID: 33380872
[TBL] [Abstract][Full Text] [Related]
38. The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer.
Wallace K; Adamski K; Pai A; Rose D; Chawla A
Pharmacoeconomics; 2021 Feb; 39(2):231-241. PubMed ID: 33145712
[TBL] [Abstract][Full Text] [Related]
39. Current and emerging biomarkers in metastatic colorectal cancer.
Lee MKC; Loree JM
Curr Oncol; 2019 Nov; 26(Suppl 1):S7-S15. PubMed ID: 31819705
[TBL] [Abstract][Full Text] [Related]
40. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
